Orum Therapeutics, Inc.
KOSDAQ-listed biotech developing its TPD² (Dual-precision Targeted Protein Degradation) DAC platform, led by its GSPT1-targeting degrader candidate.
As of 2026-10-11, Orum Therapeutics, Inc. has 2 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).
Price
Change
Market cap
Business overview
Source: DART corporate disclosureFounded in 2016 and listed on KOSDAQ in 2025, Orum Therapeutics is a biotech specializing in antibody-drug conjugate (ADC) and targeted protein degradation (TPD) technology. It has developed the TPD² (Dual-precision Targeted Protein Degradation, DAC) platform combining ADC and TPD technologies, and based on this built the TPD²-GSPT1 platform targeting the GSPT1 (G1 to S phase transition 1) protein with its proprietary payload SMol006. TPD²-GSPT1 delivers the degrader selectively to cancer cells via the antibody, which has been shown to increase efficacy more than 1,000-fold compared to small-molecule TPD drugs.
Global clinical trials
ClinicalTrials.gov · sponsor-matched- Subsidiary: Orum Therapeutics USA, Inc.Study of ORM-1153 in Acute Myeloid Leukemia (AML) With CD123 Expression
Phase 1 · Not yet recruiting · 2026-12 · NCT07809906
- Subsidiary: Orum Therapeutics USA, Inc.Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
Phase 1 · Terminated · 2022-10 · NCT05511844
R&D and key agreements
Source: DART corporate disclosureTPD²(Dual-precision Targeted Protein Degradation) · 플랫폼 기술 · DAC platform combining ADC and targeted protein degradation technology
TPD²-GSPT1 · 플랫폼/후보물질 · GSPT1-targeting degrader payload (SMol006); shown to increase efficacy over 1000-fold versus small-molecule TPD drugs
Key disclosures
KRX KIND via OpenDARTPublications
PubMed · affiliation-matched- Direct targeting of oncogenic RAS mutants with a tumor-specific cytosol-penetrating antibody inhibits RAS mutant-driven tumor growth.
Science advances · 2020-01 · Shin SM, Kim JS, Park SW 외 6
- Engineering of a tumor cell-specific, cytosol-penetrating antibody with high endosomal escape efficacy.
Biochemical and biophysical research communications · 2018-09 · Kim JS, Park JY, Shin SM 외 5
Patents
KIPRIS · applicant-matchedTW · Published · 2025-09 · Application 114137756
CN · Published · 2023-10 · Application 202380073319.4
TW · Published · 2023-10 · Application 112138604
EP · Published · 2023-10 · Application 23874420.5
US · Published · 2023-10 · Application 19118644
PCT · Published · 2023-10 · Application PCT/IB2023/060064
Published · 2023-10 · Application 1020257010924
CN · Published · 2023-03 · Application 202380038186.7
TW · Published · 2023-03 · Application 112108579
EP · Published · 2023-03 · Application 23766230.9
Show 62 more patents
US · Published · 2023-03 · Application 18845298
PCT · Published · 2023-03 · Application PCT/IB2023/052217
Published · 2023-03 · Application 1020247033423
CN · Published · 2022-09 · Application 202280073943.X
TW · Published · 2022-09 · Application 111133968
EP · Published · 2022-09 · Application 22866845.5
US · Published · 2022-09 · Application 18690506
PCT · Published · 2022-09 · Application PCT/IB2022/058428
Published · 2022-09 · Application 1020247011575
CN · Published · 2022-06 · Application 202280052606.2
CN · Published · 2022-06 · Application 202411248905.0
CN · Published · 2022-06 · Application 202280039908.6
TW · Published · 2022-06 · Application 111120734
TW · Published · 2022-06 · Application 111120735
EP · Published · 2022-06 · Application 22815473.8
EP · Published · 2022-06 · Application 22815474.6
US · Published · 2022-06 · Application 18566805
US · Published · 2022-06 · Application 18566822
PCT · Published · 2022-06 · Application PCT/IB2022/055168
PCT · Published · 2022-06 · Application PCT/IB2022/055167
Published · 2022-06 · Application 1020247000100
Published · 2022-06 · Application 1020247000099
CN · Published · 2021-03 · Application 202180025882.5
EP · Published · 2021-03 · Application 21779309.0
EP · Published · 2021-03 · Application 21780505.0
US · Published · 2021-03 · Application 17995005
US · Published · 2021-03 · Application 17995006
PCT · Published · 2021-03 · Application PCT/IB2021/052713
PCT · Published · 2021-03 · Application PCT/IB2021/052715
Published · 2021-03 · Application 1020227037930
Published · 2021-03 · Application 1020227037931
US · Published · 2020-08 · Application 16996864
PCT · Published · 2020-01 · Application PCT/KR2020/000679
Rejected · 2020-01 · Application 1020200004848
Expired · 2019-11 · Application 1020190150582
US · Registered · 2019-06 · Application 16447804
PCT · Published · 2019-06 · Application PCT/IB2019/055193
Rejected · 2019-06 · Application 1020190073548
PCT · Published · 2018-12 · Application PCT/KR2018/016844
Expired · 2018-12 · Application 1020180172312
CN · Published · 2018-11 · Application 201880085046.4
EP · Published · 2018-11 · Application 18884473.2
US · Published · 2018-11 · Application 16764517
PCT · Published · 2018-11 · Application PCT/KR2018/014110
JP · Published · 2018-11 · Application 32545033
Expired · 2018-11 · Application 1020180141770
Withdrawn · 2018-10 · Application 1020180124391
CN · Published · 2017-05 · Application 201780042608.2
EP · Published · 2017-05 · Application 17803124.1
US · Registered · 2017-05 · Application 16304444
PCT · Published · 2017-05 · Application PCT/KR2017/005559
Rejected · 2017-05 · Application 1020170065670
Registered · 2016-05 · Application 1020160065365
Rejected · 2016-05 · Application 1020160065379
Expired · 2016-02 · Application 1020160016637
CN · Published · 2015-07 · Application 201580045139.0
EP · Registered · 2015-07 · Application 15825508.3
EP · Registered · 2015-07 · Application 15825418.5
US · Registered · 2015-07 · Application 15327539
US · Registered · 2015-07 · Application 15327369
JP · Registered · 2015-07 · Application 29525495
JP · Registered · 2015-07 · Application 29525496
AI reads
MAA server logs · IP-verifiedPulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.
Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.
Collected as raw material for future answers.
Queries from users who connected this index to their own AI.
- OpenAIChatGPT-Userlive6
- OpenAIOAI-SearchBot39
- PerplexityPerplexityBot3
- AnthropicClaudeBot2
- GoogleGoogleOther1
Measured since Aug 25, 2026 · 4 AI engines · last read Oct 9, 2026
User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.
Connect this company index directly to your AI
Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Orum Therapeutics, Inc. and every listed Korean medical, bio and AI company.
How to connect (MCP)Companies in the same categoryBiotech & Drug Discovery
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Drug delivery system company behind the long-acting injectable platform IVL-DrugFluidic and the LNP delivery platform IVL-GeneFluidic.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
A holding company overseeing 54 affiliates including its main biopharmaceutical subsidiary GC, with no direct product manufacturing of its own.
Founded in 2015 and listed on KOSPI in 2021, Prestige BioPharma develops antibody biosimilars and novel antibody drugs including Tuznue.
KOSDAQ-listed biotech company developing molecular diagnostics with proprietary C-Tag technology and the NeoPlex product line.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Sources and updates
Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- Approvals & clinical trials
- Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
- Key disclosures
- KRX KIND via OpenDART exchange filings — updated daily
- Global clinical trials
- ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
- Financials
- DART corporate disclosure filings — annual
- Publications
- PubMed (US National Library of Medicine) — affiliation-matched, updated daily
- Patents
- KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
- AI reads
- Our server logs, IP-verified every 6 hours
- AI visibility
- Measured 2026-10-01
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition